Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab in addition to chemotherapy for stage IV non-squamous non-small-cell lung cancer – first line	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in Addition to Chemotherapy for Stage IV Squamous Non-Small Cell Lung Cancer – First Line	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in combination with cobimetinib for BRAF wild-type metastatic melanoma – first line	Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate)	Melanoma	Skin Cancer	2018	View \| Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Avacopan in addition to standard of care for ANCA-associated vasculitis	Avacopan (CCX168)	Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)	Cardiovascular System , Immunology	2018	View \| Download
Avelumab in combination with axitinib for advanced or metastatic renal cell carcinoma – first line	Avelumab (Bavencio; MSB-0010718C) , Axitinib (Inlyta; AG-013736)	Renal cell carcinoma (RCC)	Renal Cancer	2018	View \| Download
Avelumab with or without Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer – second line	Avelumab (Bavencio; MSB-0010718C) , Pegylated liposomal doxorubicin	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download
AVXS-101 for spinal muscular atrophy	Onasemnogene abeparvovec (Zolgensma; AVXS-101; scAAV9.CB.SMN)	Spinal muscular atrophy (SMA)	Genetic Disorders , Musculoskeletal System	2018	View \| Download
Axalimogene Filolisbac for Cervical Cancer – Beyond First Line Treatment	Axalimogene filolisbac (ADXS11-001)	Cervical cancer	Female Reproductive Cancer	2018	View \| Download